Today, life sciences and healthcare technology leader Arrayit Corporation announced that they recently made a technological breakthrough in the speed and efficiency in the manufacturing of its proprietary microarrays. The advance allows highly precise printing of as many as 2.4 million microarrays per year with a single robotic workstation, a significant increase over the current annual capacity of 640,000 microarrays per instrument.

Todd Martinsky, Arrayit Executive Vice President and Co-Founder, commented, “This technological advance represents an engineering tour de force that combines our expertise in laboratory automation, linear drive robotics, micromachining, surface chemistry and contact printing. Leveraging our core tech competencies and patented contact printing platform in this manner should further enhance our competitive differentiation in the diagnostics market.”

In other company news, Arrayit is focused on developing early stage definitive diagnostic tests for Ovarian Cancer, Parkinson’s Disease, H1N1 and other illnesses. The Pre-Symptomatic Ovarian Cancer Diagnostic Test, OvaDx(TM), will be marketed and sold by the company’s Houston-based subsidiary Arrayit Diagnostics, Inc. The worldwide market for OvaDx(TM) is estimated at 175 million microarray tests annually.